Significant rise in number of recruiting sites in China, study shows

29 June 2021

Virtual clinical development specialist Phesi has published a new data analysis on growth in recruiting clinical trial sites in China since the beginning of 2018.

The analysis finds a significant rise in the number of recruiting sites in the country, with a 163% increase between January 2018 and January 2021.

"The pandemic has led to an increasing trend towards conducting clinical trials outside of the USA and Western Europe"Interestingly, the data shows that the impact of the pandemic was far greater on the clinical trials industry in Western Europe and the USA, compared to the sustained growth of China’s pharmaceutical industry.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK